Use_NN
of_IN
arsenic_JJ
trioxide_NN
-LRB-_-LRB-
As2O3_NN
-RRB-_-RRB-
in_IN
the_DT
treatment_NN
of_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
:_:
II_CD
._.

Clinical_JJ
efficacy_NN
and_CC
pharmacokinetics_NNS
in_IN
relapsed_JJ
patients_NNS
._.

The_DT
therapeutic_JJ
effect_NN
of_IN
arsenic_JJ
trioxide_NN
-LRB-_-LRB-
As2O3_NN
-RRB-_-RRB-
in_IN
the_DT
treatment_NN
of_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
was_VBD
evaluated_VBN
among_IN
15_CD
APL_NN
patients_NNS
at_IN
relapse_NN
after_IN
all-trans_JJ
retinoic_JJ
acid_NN
-LRB-_-LRB-
ATRA_NN
-RRB-_-RRB-
induced_VBD
and_CC
chemotherapy_NN
maintained_VBD
complete_JJ
remission_NN
-LRB-_-LRB-
CR_NN
-RRB-_-RRB-
._.

As2O3_NN
was_VBD
administered_VBN
intravenously_RB
at_IN
the_DT
dose_NN
of_IN
10_CD
mg\/d_NN
._.

Clinical_JJ
CR_NN
was_VBD
achieved_VBN
in_IN
nine_CD
of_IN
10_CD
-LRB-_-LRB-
90_CD
%_NN
-RRB-_-RRB-
patients_NNS
treated_VBN
with_IN
As2O3_NN
alone_RB
and_CC
in_IN
the_DT
remaining_VBG
five_CD
patients_NNS
treated_VBN
by_IN
the_DT
combination_NN
of_IN
As2O3_NN
and_CC
low-dose_JJ
chemotherapeutic_JJ
drugs_NNS
or_CC
ATRA_NN
._.

During_IN
the_DT
treatment_NN
with_IN
As2O3_NN
,_,
there_EX
was_VBD
no_DT
bone_NN
marrow_NN
depression_NN
and_CC
only_RB
limited_VBN
side_JJ
effects_NNS
were_VBD
encountered_VBN
._.

Pharmacokinetic_JJ
studies_NNS
,_,
which_WDT
were_VBD
performed_VBN
in_IN
eight_CD
patients_NNS
,_,
showed_VBD
that_IN
after_IN
a_DT
peak_JJ
level_NN
of_IN
5.54_CD
micromol\/L_NN
to_TO
7.30_CD
micromol\/L_NN
,_,
plasma_NN
arsenic_NN
was_VBD
rapidly_RB
eliminated_VBN
,_,
and_CC
the_DT
continuous_JJ
administration_NN
of_IN
As2O3_NN
did_VBD
not_RB
alter_VB
its_PRP$
pharmacokinetic_JJ
behaviors_NNS
._.

In_IN
addition_NN
,_,
increased_VBN
amounts_NNS
of_IN
arsenic_NN
appeared_VBD
in_IN
the_DT
urine_NN
,_,
with_IN
a_DT
daily_JJ
excretion_NN
accounting_VBG
for_IN
approximately_RB
1_CD
%_NN
to_TO
8_CD
%_NN
of_IN
the_DT
total_JJ
daily_JJ
dose_NN
administered_VBN
._.

Arsenic_JJ
contents_NNS
in_IN
hair_NN
and_CC
nail_NN
were_VBD
increased_VBN
,_,
and_CC
the_DT
peak_JJ
content_NN
of_IN
arsenic_NN
could_MD
reach_VB
2.5_CD
to_TO
2.7_CD
microg\/g_NN
tissue_NN
at_IN
CR_NN
._.

On_IN
the_DT
other_JJ
hand_NN
,_,
a_DT
decline_NN
of_IN
the_DT
arsenic_JJ
content_NN
in_IN
hair_NN
and_CC
nail_NN
was_VBD
observed_VBN
after_IN
withdrawal_NN
of_IN
the_DT
drug_NN
._.

We_PRP
conclude_VBP
that_IN
As2O3_NN
treatment_NN
is_VBZ
an_DT
effective_JJ
and_CC
relatively_RB
safe_JJ
drug_NN
in_IN
APL_NN
patients_NNS
refractory_JJ
to_TO
ATRA_NN
and_CC
conventional_JJ
chemotherapy_NN
._.

